Literature DB >> 24549932

White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.

Haesook T Kim1, David Frederick, Philippe Armand, Emily Andler, Grace Kao, Corey Cutler, John Koreth, Edwin P Alyea, Joseph H Antin, Robert J Soiffer, Jerome Ritz, Vincent T Ho.   

Abstract

To determine whether outcome after allogeneic hematopoietic cell transplantation (HCT) could be estimated by using peripheral white blood cell count (WBC) as a metric that integrates several aspects of HCT recovery, we conducted a retrospective study of 1,109 adult patients who underwent first allogeneic HCT from 2003 through 2009. WBC at 1-3 months after HCT was categorized as low (<2), normal (2-10), and high (>10 × 10(9) cells/L). Overall survival (OS) and progression-free survival (PFS) were lower for patients with low or high WBC at 1-3 months after HCT (P < 0.0001). We developed a predictive three-group risk model based on the pattern of WBC recovery early after HCT. Five-year OS was 47, 30, and 15% (P < 0.0001) and 5-year PFS was 39, 22, and 14% for patients in the three different risk groups (P < 0.0001). The pattern of WBC recovery early after HCT provides prognostic information for relapse, nonrelapse mortality, progression-free survival, and overall survival. A scoring system based on the trajectory of the WBC in the first 3 months after HCT can effectively stratify patients into three groups with different PFS and OS. If validated, this system could be useful in the clinical management of patients after HCT, and to stratify patients enrolled on HCT clinical trials.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24549932      PMCID: PMC4031274          DOI: 10.1002/ajh.23695

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

1.  Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT.

Authors:  L Bühlmann; A S Buser; N Cantoni; S Gerull; A Tichelli; A Gratwohl; M Stern
Journal:  Bone Marrow Transplant       Date:  2010-11-29       Impact factor: 5.483

2.  Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation.

Authors:  D H Kim; S K Sohn; D I Won; N Y Lee; J S Suh; K B Lee
Journal:  Bone Marrow Transplant       Date:  2006-05-08       Impact factor: 5.483

3.  Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.

Authors:  Bipin N Savani; Stephan Mielke; Katayoun Rezvani; Aldemar Montero; Agnes S Yong; Laura Wish; Jeannine Superata; Roger Kurlander; Anurag Singh; Richard Childs; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-24       Impact factor: 5.742

4.  Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies.

Authors:  Katarina Le Blanc; A John Barrett; Marie Schaffer; Hans Hägglund; Per Ljungman; Olle Ringdén; Mats Remberger
Journal:  Biol Blood Marrow Transplant       Date:  2009-09       Impact factor: 5.742

5.  The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation.

Authors:  Roberta Fedele; Massimo Martino; Cristina Garreffa; Giuseppe Messina; Giuseppe Console; Domenica Princi; Antonella Dattola; Tiziana Moscato; Elisabetta Massara; Elisa Spiniello; Giuseppe Irrera; Pasquale Iacopino
Journal:  Blood Transfus       Date:  2012-01-24       Impact factor: 3.443

6.  Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant.

Authors:  Mary D Thoma; Tanya J Huneke; Lori J DeCook; Nicci D Johnson; Rob A Wiegand; Mark R Litzow; William J Hogan; Luis F Porrata; Shernan G Holtan
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-16       Impact factor: 5.742

7.  Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia.

Authors:  S Kumar; M G Chen; D A Gastineau; M A Gertz; D J Inwards; M Q Lacy; A Tefferi; M R Litzow
Journal:  Leukemia       Date:  2003-09       Impact factor: 11.528

8.  Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia.

Authors:  M K Ishaqi; S Afzal; A Dupuis; J Doyle; A Gassas
Journal:  Bone Marrow Transplant       Date:  2007-10-22       Impact factor: 5.483

9.  Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning.

Authors:  L J DeCook; M Thoma; T Huneke; N D Johnson; R A Wiegand; M M Patnaik; M R Litzow; W J Hogan; L F Porrata; S G Holtan
Journal:  Bone Marrow Transplant       Date:  2012-10-29       Impact factor: 5.483

10.  Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies.

Authors:  Z S Pavletic; S S Joshi; S J Pirruccello; S R Tarantolo; J Kollath; E C Reed; P J Bierman; J M Vose; P I Warkentin; T G Gross; K Nasrati; J O Armitage; A Kessinger; M R Bishop
Journal:  Bone Marrow Transplant       Date:  1998-01       Impact factor: 5.483

View more
  7 in total

1.  Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival.

Authors:  John Koreth; Haesook T Kim; Sarah Nikiforow; Edgar L Milford; Philippe Armand; Corey Cutler; Brett Glotzbecker; Vincent T Ho; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Edwin P Alyea
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-04       Impact factor: 5.742

2.  Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation.

Authors:  Xiying Ren; Qiusha Huang; Qingyuan Qu; Xuan Cai; Haixia Fu; Xiaodong Mo; Yu Wang; Yawei Zheng; Erlie Jiang; Yishan Ye; Yi Luo; Shaozhen Chen; Ting Yang; Yuanyuan Zhang; Wei Han; Feifei Tang; Wenjian Mo; Shunqing Wang; Fei Li; Daihong Liu; Xiaoying Zhang; Yicheng Zhang; Shuqing Feng; Feng Gao; Hailong Yuan; Dao Wang; Dingming Wan; Huan Chen; Yao Chen; Jingzhi Wang; Yuhong Chen; Ying Wang; Kailin Xu; Tao Lang; Xiaomin Wang; Hongbin Meng; Limin Li; Zhiguo Wang; Yanling Fan; Yingjun Chang; Lanping Xu; Xiaojun Huang; Xiaohui Zhang
Journal:  Blood Adv       Date:  2021-12-14

3.  Immune reconstitution following umbilical cord blood transplantation: IRES, a study of UK paediatric patients.

Authors:  John Girdlestone; Meera Raymond; Bronwen Shaw; Sameer Tulpule; Vikesh R Devlia; Robert Danby; Trudy Ahyee; Aurore Saudemont; Rachael Hough; Paul Veys; Annalisa Ruggeri; Ajay Vora; David I Marks; Brenda Gibson; Robert Wynn; Alejandro Madrigal; Cristina V Navarrete
Journal:  EJHaem       Date:  2020-05-21

4.  Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Authors:  Wael Saber; Jennifer R Brown; Haesook T Kim; Kwang Woo Ahn; Zhen-Huan Hu; Matthew S Davids; Virginia O Volpe; Joseph H Antin; Mohamed L Sorror; Mazyar Shadman; Oliver Press; Joseph Pidala; William Hogan; Robert Negrin; Steven Devine; Joseph Uberti; Edward Agura; Richard Nash; Jayesh Mehta; Joseph McGuirk; Stephen Forman; Amelia Langston; Sergio A Giralt; Miguel-Angel Perales; Minoo Battiwalla; Gregory A Hale; Robert Peter Gale; David I Marks; Mehdi Hamadani; Sid Ganguly; Ulrike Bacher; Hillard Lazarus; Ran Reshef; Gerhard C Hildebrandt; Yoshihiro Inamoto; Jean-Yves Cahn; Melhem Solh; Mohamed A Kharfan-Dabaja; Nilanjan Ghosh; Ayman Saad; Mahmoud Aljurf; Harry C Schouten; Brian T Hill; Attaphol Pawarode; Tamila Kindwall-Keller; Nakhle Saba; Edward A Copelan; Sunita Nathan; Amer Beitinjaneh; Bipin N Savani; Jan Cerny; Michael R Grunwald; Jean Yared; Baldeep M Wirk; Taiga Nishihori; Saurabh Chhabra; Richard F Olsson; Asad Bashey; Usama Gergis; Uday Popat; Ronald Sobecks; Edwin Alyea
Journal:  Clin Cancer Res       Date:  2019-06-28       Impact factor: 12.531

5.  Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.

Authors:  Haesook T Kim; Conner J Shaughnessy; Sharmila C Rai; Carol Reynolds; Vincent T Ho; Corey Cutler; John Koreth; Mahasweta Gooptu; Rizwan Romee; Sarah Nikiforow; Philippe Armand; Edwin P Alyea; Joseph H Antin; Catherine J Wu; Robert J Soiffer; Jerome Ritz; Jennifer R Brown
Journal:  Blood Adv       Date:  2020-09-08

6.  Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution.

Authors:  Katie Maurer; Haesook T Kim; Thomas M Kuczmarski; Heather M Garrity; Augustine Weber; Carol G Reynolds; Deborah Liney; Corey Cutler; Joseph H Antin; John Koreth; Jerome Ritz; Roman M Shapiro; Rizwan Romee; Catherine J Wu; Robert J Soiffer; Sarah Nikiforow; Vincent T Ho; Mahasweta Gooptu
Journal:  Blood Adv       Date:  2021-12-14

7.  Predictive Role of Circulating Immune Cell Subtypes Early after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia.

Authors:  Tae Woo Kim; Sung-Soo Park; Ji-Young Lim; Gi June Min; Silvia Park; Young-Woo Jeon; Seung-Ah Yahng; Seung-Hwan Shin; Sung-Eun Lee; Jae-Ho Yoon; Byung-Sik Cho; Ki-Seong Eom; Seok Lee; Hee-Je Kim; Chang-Ki Min
Journal:  Int J Stem Cells       Date:  2018-12-31       Impact factor: 2.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.